Access360
Success in China depends on understanding how policies across insurance, medicines, and medical care shape market access and commercial performance. Access360 is our real-time policy intelligence platform that tracks and interprets evolving developments in pricing, reimbursement, access, and care delivery—translating them into market-grounded, cross-portfolio insights to guide strategic decisions, including:
- Early insight into China access shifts impacting global pricing, margins, and launch sequencing — supporting risk-adjusted trade-offs
- Visibility into revenue risks, growth drivers, and execution challenges within China’s policy environment
- Alignment of China policy trends with launch playbooks, GTM models, and brand strategy
- Portfolio-level visibility and policy context to prioritize markets, guide resource allocation, and support investment timing
With Access360, your leadership team will receive:
- Timely policy intelligence — expert interpretation of major releases, providing the context needed to understand what they really mean for global pricing, China-specific revenue risks, and growth drivers.
- Deep-dive policy series — focused explorations of high-impact topics that inform firms’ access and go-to-market strategies.
- On-the-ground implementation intelligence — insights drawn from direct conversations with leading China experts.
- Annual executive debrief (live) — a live, system-level readout to help teams connect the broader landscape and apply insights across functions.
Access360 is available through team subscriptions. To learn more, contact us today.
